Ul­ti­movac­s' melanoma vac­cine fails in PhII; Re­genxbio’s $140M of­fer­ing

Plus, news about MindMed, Ven­tyx Bio­sciences, Rakuten Med­ical and Ross Ac­qui­si­tion Corp:

Ul­ti­movacs’ melanoma vac­cine flops in PhII: When added to Bris­tol My­ers Squibb’s Yer­voy …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER